GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Precipio Inc (NAS:PRPO) » Definitions » Cash And Cash Equivalents

Precipio (Precipio) Cash And Cash Equivalents : $1.50 Mil (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Precipio Cash And Cash Equivalents?

Precipio's quarterly cash and cash equivalents declined from Jun. 2023 ($2.57 Mil) to Sep. 2023 ($1.56 Mil) but then stayed the same from Sep. 2023 ($1.56 Mil) to Dec. 2023 ($1.50 Mil).

Precipio's annual cash and cash equivalents declined from Dec. 2021 ($11.67 Mil) to Dec. 2022 ($3.45 Mil) and declined from Dec. 2022 ($3.45 Mil) to Dec. 2023 ($1.50 Mil).


Precipio Cash And Cash Equivalents Historical Data

The historical data trend for Precipio's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precipio Cash And Cash Equivalents Chart

Precipio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.85 2.66 11.67 3.45 1.50

Precipio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.45 2.14 2.57 1.56 1.50

Precipio Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Precipio  (NAS:PRPO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Precipio Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Precipio's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Precipio (Precipio) Business Description

Traded in Other Exchanges
N/A
Address
4 Science Park, New Haven, CT, USA, 06511
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings.
Executives
Richard A Sandberg director 330 NEVEDA STREET, NEWTON MA 02460-1458
Ahmed Zaki Sabet officer: Chief Operations Officer 33 ANDYS DR, EAST HAVEN CT 06512
Ilan Danieli director, officer: Chief Executive Officer 14707 CALIFORNIA STREET, SUITE 5, OMAHA NE 68154
Matthew Gage officer: Chief Financial Officer 56 STAGECOACH CIRCLE, MILFORD CT 06460
David Seth Cohen director, 10 percent owner C/O STANDARD OIL, 299 BISHOP AVENUE, BRIDGEPORT CT 06610
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Kathleen Laporte director
Robert Patzig director THE GOVERNOR TYLER, 1881 GROVE AVENUE, RADFORD VA 24141
Michael A Luther director 21 CORPORATE CIRCLE, ALBANY NY 12203
Jeffrey Cossman director C/O PRECIPIO INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Samuel D Riccitelli director 2850 FRONTIER DR., WARSAW IN 46582
Carl Iberger officer: Chief Financial Officer C/O PRECIPIO, INC., 12325 EMMET STREET, OMAHA NE 68164
Douglas Fisher director 587 PATROL RD, WOODSIDE CA 94062
Mark Rimer director, 10 percent owner C/O PRECIPIO, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511